Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 2/20 | 0.40 |
| ▸ | ESR1 | P03372 | 4/20 | 0.37 |
| ▸ | AR | P10275 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10097261 | 0.95 | AR (0.40) | KIF11ESR1ARKDM4EMEN1 | |
| SCHEMBL10095454 | 0.88 | AR (0.43) | KIF11ESR1ARKDM4EMEN1 | |
| SCHEMBL10095394 | 0.87 | KDM4E (0.37) | KIF11ESR1ARKDM4EMEN1 | |
| SCHEMBL10191023 | 0.87 | ALDH1A1 (0.43) | ESR1ARKDM4EMEN1ALDH1A1 | |
| SCHEMBL10191034 | 0.86 | ESR1 (0.39) | ESR1ARKDM4EMEN1ALDH1A1 | |
| SCHEMBL10251575 | 0.85 | USP7 (0.37) | KIF11ESR1ESR2SRCPRKACA | |
| SCHEMBL10191026 | 0.84 | GRIK2 (0.47) | ESR1KDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL10097265 | 0.81 | AR (0.39) | KIF11ARKDM4EMEN1ALDH1A1 | |
| SCHEMBL10097259 | 0.80 | KIF11 (0.39) | KIF11KDM4EALDH1A1HTTS1PR1 | |
| SCHEMBL10191021 | 0.80 | KDM4E (0.38) | ESR1KDM4EMEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | OAT, HAVCR2, HCCS | KIF11 3319/4885ESR1 4618/4885AR 4848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.